Index
reoperative 140, 144, 151
surgery 141, 145
CAC 336–43
CACNA1C 239
CACNP 340–2
CACP 336–8, 342–3
CAD 13, 153–5, 160–1, 163, 204–5, 208, 215–6, 225–6,
231–2, 258–9, 261, 279, 297, 299, 306, 336, 338–40,
343
Calcifi cation 297, 343
coronary 336, 338–40, 342
Calcium 17, 225, 282–3
channel blockers. See CCBs
scanning 338–9
scores 336–9, 342–3
Canadian Amiodarone Myocardial Infarction Arrhythmia
Trial 281
Canadian Atrial Fibrillation Anticoagulation 247
Canadian Implantable Defi brillator Study 273, 278
Candesartan 64, 68, 209
Capacity, functional 155, 158
Captopril 227
Carbohydrates 189, 193
Cardiac Arrest Study Hamburg 273, 278
Cardiac Pacemakers and Antiarrhythmia Devices 282
Cardiac rehabilitation 91–107
Cardiac Rehabilitation/Secondary Prevention. See CR/SP
Cardiomyopathy 17, 158, 230, 236–43, 282, 284–5, 288–
9, 291, 338
defi ned 236
hypertrophic 284–5, 291
infi ltrative 282
ischemic 292
primary 237, 241
restrictive 241–2
RV 274, 284
secondary 237, 241
tachycardia-induced 253, 275
tachycardia-mediated 246
Cardiomyopathy Trial 279
Cardioplegia, blood 138–9
Cardiopulmonary
bypass 136
resuscitation 50, 276
Cardiovascular disease. See CVD
Cardioversion 245, 249, 251–2, 258–9, 265–8, 270, 276–
7, 289, 291
electrical 246, 251
pharmacological 249
synchronized 75
Cardioverter-defi brillator, implantable 230
Carnitine 240–1
Carotene, beta 216, 220
Carteolol 227
Carvajal syndrome 239
Carvedilol 206, 209, 227
CASHD 136–7, 142–4, 150–1
Catecholaminergic polymorphic ventricular tachycardia.
See CPVT
Catecholamine 260
Categories, Rutherford 181
Catheter Ablation compared with Pharmacological
Therapy for Atrial Fibrillation 254
Catheter 162–3, 331
Catheterization 52, 72, 78–9, 81–3
cardiac 52, 68, 297–303, 306, 338, 341
Caveolin 241
CCBs 33, 43, 64–5, 70, 204, 206–8, 212–3, 229, 261–3,
265, 276, 288
dihydropyridine 204
nondihydropyridine 33–4, 140
CD 143, 154–6, 158, 160–1, 197–200, 210–2
Cell junction disease 239
Cerebrovascular accident 138
Chagas disease 240–1
Channelopathies 236
CHD 117, 187–92, 194–5, 206, 212–3, 221, 239, 273–5,
288, 294, 334
unrepaired cyanotic 294
CHF 58, 61, 81, 83, 322, 326, 328, 331
Chlorothiazide 228
Chlorpromazine 290
Chlorthalidone 228
Cholesterol 43–4, 67, 109, 141, 173, 187–9, 191–2, 194–5
Cholestyramine 190
Chronic kidney disease. See CKD
Chronic obstructive pulmonary disease 143
Cilostazol 177–8
Cisapride 290
CK-MB 32, 118, 139
CKD 44, 48, 196, 200, 202, 204, 210–1
defi ned 211
ALLHAT 208
Clarithromycin 290, 335
Claudication 166–8, 170–2, 174–80
Exercise vs. Endoluminal Revascularization 186
intermittent 168, 176, 178–80
symptoms 168, 171, 175–6, 178, 180–1
Critical limb ischemia (CLI) 168–9, 181–3, 185
Clindamycin 335
Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation Trial 132, 349–50
Clofi brate 190
Clonidine 204, 210
Clopidogrel 26, 28, 34–8, 41–2, 45, 63, 68, 81, 84, 86, 89,
109–10, 114, 130, 141, 145, 216, 220, 248–9